Liv Hospital integrates PET/CT diagnostics, radionuclide therapies and a multidisciplinary council to create individualized treatment plans for complex cancer and cardiac cases.
Highlights of the conference coverage from the 2025 European Society of Medical Oncology (ESMO) Congress included content on ...
Treating PSMA-positive patients with mHSPC with the radioligand 177Lu-PSMA-617 on top of standard of care reduces their risk for radiographic progression or death. In patients with PSMA-positive ...
TipRanks on MSN
Fosun Pharma subsidiary launches phase I trial of PSMA radiopharmaceutical for advanced prostate cancer
The latest announcement is out from Shanghai Fosun Pharmaceutical (Group) Co ( ($HK:2196) ). Shanghai Fosun Pharmaceutical’s subsidiary Chengdu ...
Tribune Content Agency on MSN
Can men hold off on treating recurring prostate cancer?
What happens if PSA levels start rising after surgery or radiation for prostate cancer? Up to a third of men treated for the disease will eventually confront this problem. If there's no accompanying ...
Francis Medical is heating up with a 510(k) clearance from the FDA for its water vapor ablation therapy aimed at cancers of the prostate, kidneys and bladder. The regulatory go-ahead for its Vanquish ...
Patients who received ADT for 3 months or 9 months had worse overall survival than those treated for 36 months. For men with prostate cancer treated with definitive radiotherapy, the benefit derived ...
Learn about the clinical trials and research at MSK that led to 11 FDA approvals in 2025, expanding treatment options for a range of different cancers.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback